International

The international activity of the Rekah Group is carried out in several channels:

Export
Rekah Group's export activity is focused on the ophthalmologic, steroid and specialty products.
The company develops itself and maintains collaborations to expand the product line and ad-dresses the domestic market and international markets, with an emphasis on the European mar-ket.
The group exports several products to a major market in Europe and the Far East and in registra-tion procedures in markets in Europe, North America, and Asia.
In 2021 the group launched a core product in a central western country and there is registration and registration operations at various stages in other countries in Europe and North America.
Import
The Rekah Group has a diverse portfolio that includes about 300 products and an independent marketing capability that reaches all customers throughout the country.
The group is active in the market of hospitals, health funds and pharmacies and works to register generic products in the field of antibiotics, metabolic diseases, and other products in Israel.
Rekah is looking for international partners to license complementary and synergistic products for its activities in the domestic and international market.
Collaborations
Rekach Group develops itself and is looking for partners for technology transfer and technology absorption and co-developments in the core areas of its activities.
The company is also looking for joint ventures in areas that support the company's strategy and focus on overseas markets.

In 2021, Rekah acquired “Tree of Life”, a company that develops, manufactures, imports, markets and sells innovative medical devices and health products. This is the first strategic and synergistic acquisition of the Rekah Group, which allows it to enter the growing medical device field in Israel and around the world. This acquisition opens the door to a significant growth channel in Israel and abroad by immediate-ly expanding the product portfolio with innovative products in new areas, marketing registration and distribution infrastructure in foreign markets, regulatory capabilities, and development in the field of medical devices. The acquisition of “Tree of Life” strengthens the position of the Rekah Group as a leading pharmaceutical company in Israel.

Out-Licensing

In-Licensing

Partnerships and M&A

Rekah is working to increase its international presence, focusing on the EU and other eCTD-based countries such as the Canada, Australia and others.

Our two manufacturing sites meet the EU’s GMP under the Mutual Recognition Agreements (MRAs) treaty between the Israeli Ministry of Health and the European Commission.

We are investing in R&D, regulatory and manufacturing capabilities for producing new generic products, and development of unique niche products to meet market requirements overseas.

We look for strategic collaborations in markets where our core products have a strong competitive added value.

REKAH PHARMACEUTICALS’ GENERICS FOR EXPORT 2022

Rekah is engaged in all aspects of the pharmaceuticals’ value chain - from manufacturing, importing, and marketing to distributing to the customer's doorstep.

Rekah owns a variety of marketing authorizations in Israel for several prescription drugs which are manufactured abroad.

At Rekah, we are looking for opportunities to expand our portfolio with additional complementary products.

Rekah is working to expand its business operations and achieve an international footprint, focusing on Europe.

Rekah seeks strategic partnerships that will enable it to expand its product portfolio, shorten its time to market (TTM) and obtain regulatory license in its chosen markets.

With strong financial backing, we aim to extend our business activities and make an international footprint, focusing on Europe and European-oriented pharmaceutical businesses.

IN-LICENSING

Rekah is engaged in all aspects of the pharmaceuticals’ value chain - from manufacturing, importing, and marketing to distributing to the customer's doorstep.

Rekah owns a variety of marketing authorizations in Israel for several prescription drugs which are manufactured abroad.

At Rekah, we are looking for opportunities to expand our portfolio with additional complementary products.

IN-LICENSING

Rekah is engaged in all aspects of the pharmaceuticals’ value chain - from manufacturing, importing, and marketing to distributing to the customer's doorstep.
Rekah owns a variety of marketing authorizations in Israel for several prescription drugs which are manufactured abroad.
At Rekah, we are looking for opportunities to expand our portfolio with additional complementary products.

OUT-LICENSING

Rekah is working to increase its international presence, focusing on the EU and other eCTD-based countries such as the Canada, Australia and others.

Our two manufacturing sites meet the EU’s GMP under the Mutual Recognition Agreements (MRAs) treaty between the Israeli Ministry of Health and the European Commission.

We are investing in R&D, regulatory and manufacturing capabilities for producing new generic products, and development of unique niche products to meet market requirements overseas.

We look for strategic collaborations in markets where our core products have a strong competitive added value.

REKAH PHARMACEUTICALS’ GENERICS FOR EXPORT 2022

IN-LICENSING

Rekah is engaged in all aspects of the pharmaceuticals’ value chain - from manufacturing, importing, and marketing to distributing to the customer's doorstep.

Rekah owns a variety of marketing authorizations in Israel for several prescription drugs which are manufactured abroad.

At Rekah, we are looking for opportunities to expand our portfolio with additional complementary products.

PARTNERSHIPS AND M&A

Rekah is working to expand its business operations and achieve an international footprint, focusing on Europe.

Rekah seeks strategic partnerships that will enable it to expand its product portfolio, shorten its time to market (TTM) and obtain regulatory license in its chosen markets.

With strong financial backing, we aim to extend our business activities and make an international footprint, focusing on Europe and European-oriented pharmaceutical businesses.

OUT-LICENSING

Rekah is working to increase its international presence, focusing on the EU and other eCTD-based countries such as the Canada, Australia and others.
Our two manufacturing sites meet the EU’s GMP under the Mutual Recognition Agreements (MRAs) treaty between the Israeli Ministry of Health and the European Commission.
We are investing in R&D, regulatory and manufacturing capabilities for producing new generic products, and development of unique niche products to meet market requirements overseas.
We look for strategic collaborations in markets where our core products have a strong competitive added value.
REKAH PHARMACEUTICALS’ GENERICS FOR EXPORT 2022
IN-LICENSING

Rekah is engaged in all aspects of the pharmaceuticals’ value chain - from manufacturing, importing, and marketing to distributing to the customer's doorstep.
Rekah owns a variety of marketing authorizations in Israel for several prescription drugs which are manufactured abroad.
At Rekah, we are looking for opportunities to expand our portfolio with additional complementary products.
PARTNERSHIPS AND M&A

Rekah is working to expand its business operations and achieve an international footprint, focusing on Europe.
Rekah seeks strategic partnerships that will enable it to expand its product portfolio, shorten its time to market (TTM) and obtain regulatory license in its chosen markets.
With strong financial backing, we aim to extend our business activities and make an international footprint, focusing on Europe and European-oriented pharmaceutical businesses.

PARTNERSHIPS AND M&A

Rekah is working to expand its business operations and achieve an international footprint, focusing on Europe.

Rekah seeks strategic partnerships that will enable it to expand its product portfolio, shorten its time to market (TTM) and obtain regulatory license in its chosen markets.

With strong financial backing, we aim to extend our business activities and make an international footprint, focusing on Europe and European-oriented pharmaceutical businesses.

PARTNERSHIPS AND M&A

Rekah is working to expand its business operations and achieve an international footprint, focusing on Europe.
Rekah seeks strategic partnerships that will enable it to expand its product portfolio, shorten its time to market (TTM) and obtain regulatory license in its chosen markets.
With strong financial backing, we aim to extend our business activities and make an international footprint, focusing on Europe and European-oriented pharmaceutical businesses.